About Bioptigen
Bioptigen is a company based in United States founded in 2004 was acquired by Leica Microsystems in June 2015. Bioptigen has raised $2.79 million across 16 funding rounds from investors including Leica Microsystems and HHS. The company has 25 employees as of December 31, 2014. Bioptigen operates in a competitive market with competitors including Sensimed, i-Optics, Azul Optics, Oxymap and 2EyesVision, among others.
- Headquarter United States
- Employees 25 as on 31 Dec, 2014
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bioptigen Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.79 M (USD)
in 16 rounds
-
Latest Funding Round
$1.72 M (USD), Grant
Sep 30, 2014
-
Investors
Leica Microsystems
& 1 more
-
Employee Count
25
as on Dec 31, 2014
-
Acquired by
Leica Microsystems
(Jun 01, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Bioptigen
Bioptigen has successfully raised a total of $2.79M across 16 strategic funding rounds. The most recent funding activity was a Grant round of $1.72 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bioptigen
Bioptigen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Leica Microsystems and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Imaging solutions for macro, micro, and nano structures are provided.
|
Locked | Locked | Locked |
Investor details for Bioptigen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bioptigen
Investment portfolio details for Bioptigen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bioptigen
Detailed financials for Bioptigen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bioptigen Comparisons
Peer comparison for Bioptigen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bioptigen
Bioptigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sensimed, i-Optics, Azul Optics, Oxymap and 2EyesVision, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A contact lens-based platform for glaucoma monitoring is offered.
|
|
| Locked | Locked | Locked |
i-Optics specializes in providing advanced retina and cornea imaging systems for medical professionals.
|
|
| Locked | Locked | Locked |
Device for assessing the eye health against damaging light
|
|
| Locked | Locked | Locked |
Retinal Imaging technology to assess retinal oxygen saturation and vessel width
|
|
| Locked | Locked | Locked |
Portable technologies for multifocal eye corrections before surgeries are developed.
|
Detailed competitors of Bioptigen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioptigen
Complete news archive for Bioptigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioptigen
Bioptigen was founded in 2004.
Bioptigen is headquartered in United States.
Bioptigen is a funded company, having raised a total of $2.79M across 16 funding rounds to date.
As of Dec 31, 2014, the latest employee count at Bioptigen is 25.
Bioptigen develops Optical Coherence Tomography (OCT) devices with Spectral domain imaging(SDI). While all OCT techniques use interferometry to create cross-sectional views of different types of tissue, the SD-OCT approach offers faster scanning speeds than the earlier time-domain approach, making it more suited to real-time surgical use. Bioptigen is an ISO 13485-certified medical device company that develops ophthalmic imaging solutions. Bioptigens Envisu R-class systems is for non-invasive ophthalmic imaging of animals. Using low-power, near-infrared light, Envisu generates real-time, volumetric images of ocular microstructures from the cornea to the retina. Bioptigen has received CE approval to market its hand-held Envisu R2000 systems for preclinical use and C2000 systems for clinical use within the EU.
Bioptigen's top competitors include 2EyesVision, Sensimed and Diopsys.
Bioptigen has 2 investors. Key investors include Leica Microsystems, and HHS.